InMed Pharmaceuticals (NASDAQ: INM)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.250 | ||||||
REV | 309.585K |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.310 | -0.0800 | ||||
REV | 120.000K | 265.092K | 145.092K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of InMed Pharmaceuticals (NASDAQ: INM) through any online brokerage.
There are no as such competitors for InMed Pharmaceuticals.
The latest price target for InMed Pharmaceuticals (NASDAQ: INM) was reported by HC Wainwright & Co. on Monday, November 29, 2021. The analyst firm set a price target for 6.00 expecting INM to rise to within 12 months (a possible 689.47% upside). 1 analyst firms have reported ratings in the last year.
The stock price for InMed Pharmaceuticals (NASDAQ: INM) is $0.76 last updated May 25, 2022, 8:00 PM UTC.
There are no upcoming dividends for InMed Pharmaceuticals.
InMed Pharmaceuticals’s Q3 earnings are confirmed for Friday, May 13, 2022.
There is no upcoming split for InMed Pharmaceuticals.
InMed Pharmaceuticals is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.